Avicena completes enrollment in new study for ALS
In this phase II trial, investigators will assess the efficacy, safety and tolerability of Avicena's ALS-08 drug candidate in separate combinations with two treatments, minocycline and celecoxib. The
WellSpan Health and Johns Hopkins Medicine have renewed their oncology collaboration, aiming to widen patient access to advanced care, clinical expertise, and research initiatives throughout central Pennsylvania, US.